$MOTS News

Last published 2y ago

2y agoMOTSMotus GI Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSuccessfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded
2y agoMOTSMotus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswireInitiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek
2y agoMOTSEndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive OfficerBusiness WireAldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing
2y agoMOTSMotus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross ProceedsGlobeNewswireFORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS, or "Motus" or "the Company")), a medical technology company focused on improving endoscopic outcomes and experiences,
2y agoMOTSMotus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of StockholdersGlobeNewswireFORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. ("the Company") (NASDAQ:MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the "Special Meeting")
2y agoMOTSMotus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel PreparationGlobeNewswireFORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS, or "Motus GI" or "the Company")), a medical technology company focused on improving endoscopic outcomes and experiences,
2y agoMOTSMotus GI Holdings, Inc. Announces Pricing of $5.0 Million Public OfferingGlobeNewswireFORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS, or "Motus GI" or "the Company")), a medical technology company focused on improving endoscopic outcomes and experiences,
2y agoMOTSMotus GI Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireFirst case performed using the new FDA cleared Pure-Vu® EVS Gastro system, and expect to initiate broader market introductions by the end of 2023Pure-Vu EVS Gastro addresses the Upper GI market, an area of high
3y agoMOTSMotus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS GastroGlobeNewswire- - -The upper GI procedure was performed by Dr. Brian Hanson, gastroenterologist and Assistant Professor, Medicine, at the University of Minnesota- - -Pure-Vu EVS Gastro addresses the Upper GI market, an area of high
3y agoMOTSMotus GI Announces 1-for-15 Reverse Stock SplitGlobeNewswireFORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences,
3y agoMOTSMotus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 ColonGlobeNewswire– Clearance opens up the potential breakthrough opportunity in the Upper GI market, an area of high unmet clinical need – – Technological advancements featured in new generation of the Pure-Vu platform, enhance the
3y agoMOTSMotus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and ColonGlobeNewswire– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt – – Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and minimizes the need
3y agoMOTSMotus GI Amends Royalty AgreementGlobeNewswire– Amended agreement eliminates approximately $1.0M in contingent royalty obligations from balance sheet – – Canceled royalty rights in exchange for common stock expected to improve Company's stockholder equity, and
3y agoMOTS OBIOMotus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of DirectorsGlobeNewswireFORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences,
3y agoMOTSMotus GI to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireFORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences,
3y agoMOTSMotus GI Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireOn track to submit planned special 510(k) for Pure-Vu Gen 4 Gastro and Colon to the FDA in Q4 2023;Received system wide approval in the Banner Medical Hospital Network and installed the first system at the Banner Dessert
3y agoMOTSMotus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS SystemGlobeNewswireFORT LAUDERDALE, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences,
3y agoMOTSMotus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical CenterGlobeNewswireImplementation of the Pure-Vu system designed to improve efficiencies and outcomes of GI endoscopy proceduresInitial agreement expected to provide an easier sales process to the other more than 30 medical centers within
3y agoMOTSMotus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning CenterGlobeNewswirePure-Vu system featured in live case during an underwater large polyp resection in the colonOver 1,000 physicians registered for IECED Live Endoscopy Course from across Latin AmericaPure-Vu Gen 4 Gastro and Colon on
3y agoMOTS OBIOOrchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial OfficerGlobeNewswireBill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive
3y agoMOTSMotus GI Announces Appointment of Ravit Ram as Chief Financial OfficerGlobeNewswireCompany completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers, including seeking key FDA approvals and pursuit of strategic partnerships to accelerate
3y agoMOTSMotus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireFORT LAUDERDALE, Fla., May 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today
3y agoMOTSMotus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA SubmissionGlobeNewswire- Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in Q4 2023 to support
3y agoMOTSMotus GI Announces DDW 2023 Clinical Study Presentation Showing Pure-Vu EVS Drove a 33% Hospital-Wide Improvement in Incomplete Bowel Prep Rate at Minneapolis VA Medical CenterGlobeNewswireFORT LAUDERDALE, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes
3y agoMOTSMotus GI Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire■Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu® system at the
3y agoMOTSAngel Medical Systems, Creator of the Guardian™, First Implantable Cardiac Alert System, Changes Name to Avertix Medical Inc. and Welcomes New CEO and CFO to Drive Continued Growth and SuccessGlobeNewswireNew company name chosen to represent focus on ‘averting' serious cardiac complications with state-of-the-art Guardian™ monitoring and alerting system President and CEO Tim Moran and Chief Financial Officer Philip
3y agoMOTSMotus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term MilestonesGlobeNewswireTim Moran transitions from Chief Executive Officer to Chairman of the Board and Mark Pomeranz appointed Chief Executive Officer to lead next phase of Company Restructuring plan reduces operating expenses by an
3y agoMOTSMotus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireThe Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company is actively
3y agoMOTSMotus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring PlanGlobeNewswireLake Street Capital Markets LLC engaged to act as an advisor to the CompanyBoard of Directors approved restructuring program with the objective of preserving capital to align with strategic process timelineManagement
3y agoMOTSMotus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical TestsGlobeNewswirePre-clinical tests show enhanced functionality of Pure-Vu EVS that can enable physicians to overcome common visualization challenges encountered during emergency upper GI bleeding proceduresAdditional pre-clinical and
4y agoMOTSMotus GI to Release Third Quarter Results and Provide a Business Update on November 14GlobeNewswireFORT LAUDERDALE, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve
4y agoMOTSMotus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific MeetingGlobeNewswirePositive clinical data from feasibility and efficacy study of the Pure-Vu EVS conducted by Minneapolis VA Health Care System Overview of the results from an inpatient colonoscopy conducted at an ICU bedside when using
4y agoMOTSMotus GI Named a Sole Source Supplier with U.S. Department of Veteran AffairsGlobeNewswireMultiple contracts with VA medical centers already executed for Pure-Vu EVS under the sole source supplier designation, with additional centers under evaluation Approximately 645,000 colonoscopies were performed at ~170 VA medical centers over the last
4y agoMOTSMotus GI Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswirePure-Vu EVS approved for use at 18 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's history Expansion of U.S. commercial footprint successfully driving access to new hospitals and improving sup
4y agoMOTSMotus GI Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireFORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency as
4y agoMOTSMotus GI Announces 1-FOR-20 Reverse Stock SplitGlobeNewswireFORT LAUDERDALE, Fla., July 25, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency ass
4y agoMOTSMotus GI to Release Second Quarter Results and Provide a Business Update on August 11GlobeNewswireFORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency ass
4y agoMOTSMotus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022GlobeNewswire– The Pure-Vu system improved the adequate cleansing rate more than 200% to 97.7% in patients with a history of poor bowel preparation FORT LAUDERDALE, Fla., May 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or th
4y agoMOTSMotus GI Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswirePure-Vu EVS approved for use at 11 hospitals since product launch commenced in March 2022; with strong procedural volumes and significant positive feedback Expansion of US commercial footprint ahead of schedule, with additional investments planned thr
4y agoMOTSMotus GI Announces Upcoming Presentation of Topline Data from the EU Study of the Pure-Vu System at Digestive Disease Week 2022GlobeNewswireFORT LAUDERDALE, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency asso
4y agoMOTSMotus GI to Release First Quarter Results and Provide a Business Update on May 12GlobeNewswireFORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency as
4y agoMOTSMotus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel PreparationGlobeNewswireTopline data expected to be presented at a scientific conference in May 2022 Independent data shows ~5.4M outpatient colonoscopies are performed in EU annually1 New study data expected to further aid in commercial adoption FORT LAUDERDALE, Fla., A
4y agoMOTSMotus GI Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireReceived FDA clearance in February 2022 to market Pure-Vu EVS, an all new, next-generation system that has been deployed to multiple hospitals in the first few weeks since launch Doubled the size of the sales team since November, and plan to contin
4y agoMOTSMotus GI to Release Fourth Quarter and Full Year 2021 Results and Provide a Business Update on March 29GlobeNewswireFORT LAUDERDALE, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency as
4y agoMOTSMotus GI to Participate in Two Upcoming Investor Conferences in March 2022GlobeNewswireFORT LAUDERDALE, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency as
4y agoMOTSMotus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price RequirementGlobeNewswireFORT LAUDERDALE, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency ass
4y agoMOTSMotus GI Receives FDA Clearance to Market the Pure-Vu® EVS SystemGlobeNewswire-All New Pure-Vu EVS offers rapid set-up, improved navigation and enhanced cleansing capabilities to support expanded clinical utilization -Scientific literature shows ~51% of hospitalized inpatient colonoscopies are delayed due to insufficient
4y agoMOTSMotus GI to Host Innovation Day Highlighting the Pure-Vu EVS SystemGlobeNewswireFORT LAUDERDALE, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency ass
4y agoMOTSMotus GI Announces U.S. Patent For The Pure-Vu® System's Automatic Self-Purging FeaturesGlobeNewswireFORT LAUDERDALE, Fla., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency ass
4y agoACU ALCO ALOT AMST+60Sidoti December Micro Cap Virtual ConferenceACCESS NewswirePresentation Times Released for 75+ Presenting Companies Wednesday and Thursday, December 8-9, 2021 NEW YORK, NY / ACCESSWIRE / December 7, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day December Micro